Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, announced the appointments of Edward J. Holland, M.D., as Chief Medical Officer.
Aurion Biotech is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial disease, a condition that causes progressive vision loss in millions of people worldwide.
Dr. Holland has been a key supporter of Aurion since its inception, serving as Chair of the Medical Advisory Board and leading the first team of U.S. corneal surgeons to deliver the cell therapy developed by Aurion Biotech, based on foundational technology from Professor Shigeru Kinoshita at Kyoto Prefecture University of Medicine. His insights and clinical leadership have helped shape the trajectory of Aurion’s development program.
Also Read: Atreo Launches Transformative v2.0 RTSM Platform
“I’ve had the privilege of knowing Dr. Holland for over a decade,” said Arnaud Lacoste, Ph.D., M.B.A., Chief Executive Officer of Aurion. “His dedication to patients and his leadership in corneal care have been instrumental to the success of our program. His appointment as Chief Medical Officer further strengthens our clinical and scientific foundation as we move toward late-stage development and, ultimately, broader patient access.”
Dr. Holland added, “Joining Aurion in this capacity is both exciting and deeply meaningful. I’ve seen firsthand the transformative potential of AURN001, and I look forward to helping the team bring this therapy to patients who urgently need new options.”
SOURCE: Businesswire